inflammatory
Lev Pharmaceuticals Inc. (LEVP.OB) Granted Authorization to File for European Distribution Rights for Lead Drug Candidate
Read the full article: http://blog.qualitystocks.net/?p=10898
The company announced a letter of agreement with the Sanquin Blood Supply Foundation, which gives Lev the OK to file for European marketing authorization of C1 to treat the life-threatening attacks associated with HAE, such as inflammation of the larynx, abdomen, face, extremities and urogenital tract.
- Login or register to post comments
- Read more
- Email this page
Related Articles
- Lev Pharmaceuticals Inc. (LEVP.OB) Granted Authorization to File for European Distribution Rights for Lead Drug Candidate
- AVANIR Pharmaceuticals (AVNR) Receives European Patent Approval for Extended Commercial Exclusivity for Zenair
- Government Approved Coal Permits for Micron Enviro Systems Inc. (MENV.OB)
- Deep Down, Inc’s (DPDW.OB) 3rd Quarter 2008 Revenues Skyrocket On Two Key Acquisitions
- How To Monitor Active Forex Trades?